Glycosphingolipids in congenital disorders of glycosylation (CDG).
CDG
Congenital disorders of glycosylation
GSLs
Gangliosides
Glycosphingolipids
Journal
Molecular genetics and metabolism
ISSN: 1096-7206
Titre abrégé: Mol Genet Metab
Pays: United States
ID NLM: 9805456
Informations de publication
Date de publication:
05 Mar 2024
05 Mar 2024
Historique:
received:
19
01
2024
revised:
26
02
2024
accepted:
27
02
2024
medline:
16
3
2024
pubmed:
16
3
2024
entrez:
15
3
2024
Statut:
aheadofprint
Résumé
Congenital disorders of glycosylation (CDG) are a large family of rare disorders affecting the different glycosylation pathways. Defective glycosylation can affect any organ, with varying symptoms among the different CDG. Even between individuals with the same CDG there is quite variable severity. Associating specific symptoms to deficiencies of certain glycoproteins or glycolipids is thus a challenging task. In this review, we focus on the glycosphingolipid (GSL) synthesis pathway, which is still rather unexplored in the context of CDG, and outline the functions of the main GSLs, including gangliosides, and their role in the central nervous system. We provide an overview of GSL studies that have been performed in CDG and show that abnormal GSL levels are not only observed in CDG directly affecting GSL synthesis, but also in better known CDG, such as PMM2-CDG. We highlight the importance of studying GSLs in CDG in order to better understand the pathophysiology of these disorders.
Identifiants
pubmed: 38489976
pii: S1096-7192(24)00249-X
doi: 10.1016/j.ymgme.2024.108434
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
108434Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare no conflict of interest.